Patent ID: 8633009

Claim:
An engineered Y. lipolytica strain comprising: a combination of two or more quinonogenic modifications selected from the group consisting of: a. increased expression or activity of a GGPP synthase polypeptide; b. increased expression or activity of a truncated HMG CoA reductase polypeptide; c. increased expression or activity of a 4-hydroxybenzoate polyprenyl transferase polypeptide; d. increased expression or activity of a decaprenyl diphosphate synthase polypeptide; e. increased expression or activity of a DAHP synthase polypeptide; f. increased expression or activity of a chorismate lyase polypeptide; g. increased expression or activity of a shikimate pathway polypeptide; h. increased expression or activity of a chorismate mutase polypeptide; i. increased expression or activity of a transketolase polypeptide; j. increased expression or activity of an FPP synthase polypeptide; k. increased expression or activity of an IPP isomerase polypeptide; l. increased expression or activity of an HMG-CoA synthase polypeptide; m. increased expression or activity of a mevalonate kinase polypeptide; n. increased expression or activity of a phosphomevalonate kinase polypeptide; o. increased expression or activity of a mevalonate pyrophosphate decarboxylate polypeptide; p. increased expression or activity of a cytosolic malic enzyme polypeptide; q. increased expression or activity of a malate dehydrogenase polypeptide; r. increased expression or activity of an AMP deaminase polypeptide; s. increased expression or activity of a glucose 6 phosphate dehydrogenase polypeptide; t. increased expression or activity of a malate dehydrogenase homolog2 polypeptide; v. increased expression or activity of a GND1-6-phosphogluconate dehydrogenase polypeptide; w. increased expression or activity of a isocitrate dehydrogenase polypeptide; x increased expression or activity of a IDH2-isocitrate dehydrogenase polypeptide; y. increased expression or activity of a fructose 1,6 bisphosphatase polypeptide; z. increased expression or activity of an Erg10-acetoacetyl CoA thiolase polypeptide; aa. increased expression or activity of an ATP citrate lyase subunit 2 polypeptide; bb. increased expression or activity of an ATP citrate lyase subunit 1 polypeptide; cc. increased expression or activity of a chorsimate synthase polypeptide; dd. decreased expression or activity of a squalene synthase polypeptide; ee. decreased expression or activity of a prenyldiphosphate synthase polypeptide; and ff. decreased expression or activity of a PHB polyprenyltransferase polypeptide; wherein as a result of the combination of two or more quinonogenic modifications the engineered Y. lipolytica strain produces at least one quinone derived compound to at least about 1% of its dry cell weight; and wherein the engineered strain can accumulate lipid to at least about 20% of its dry cell weight.